A 7-year-old boy with Down syndrome was diagnosed with a very rare and aggressive form of leukemia: T-cell acute lymphoblastic leukemia (T-ALL). Doctors treated him with a chemotherapy regimen designed for children with leukemia, but they had to make significant adjustments along the way because of his unique needs.
The boy's leukemia cells had a complex set of genetic changes, including a translocation (a swap of DNA between chromosomes) and a deletion. But importantly, the cancer did not show the typical fusion gene often seen in T-ALL. Instead, it had mutations in the NOTCH1 and FBXW7 genes, which are known to drive some T-cell leukemias.
Despite multiple severe complications from treatment, the boy responded well. He achieved minimal residual disease negativity, meaning no detectable cancer cells remained after therapy. He remained in remission at 15 months follow-up.
This is just one case, and the authors caution that T-ALL in Down syndrome is still poorly understood. There are no standard treatment guidelines for these rare and fragile patients. But this report suggests that intensive chemotherapy can work, and that the genetic makeup of the leukemia may be different from other types of Down syndrome leukemia.
